completionofsixcyclesofCYCtherapytherewasimprovementofherclinical symptoms with normalization of CRP. A satisfactory clinical outcome was achieved and a repeat PET-FDG showed significant improvement, but persistent diffuse tracheal thickening and narrowing. Presently, she is onazathioprine50mg/dailywithtaperingdoseoforalsteroid. Discussion: Relapsing polychondritis is an uncommon systemic disease characterized by recurrent episodes of inflammation and destruction of systemic cartilaginous tissues. It has been reported that approximately 50% of patients with relapsing polychondritis have suffered tracheal stenosis and pneumonia, which defines their prognosis (i.e., 5-year and 10-year survival rate are 74% and 55%, respectively. The airway stenosis in relapsing polychondritis is generally caused by intraluminal fibrosis, which, in turn, is caused by inflammation of the tracheobronchial cartilage. This often requires stent therapy. There is limited evidence to guide optimum therapy. Current approaches are based on case reports, case series and expert opinion. Key Learning Points: Relapsing polychondritis is an uncommon condition of cartilage destruction, which is life threatening when it affects the trachea or aortic ring. Tracheal disease is the presenting feature in 10-15% of cases. Our patient failed to respond adequately to oral steroid alone, and needed combination IV CS and CyC therapy to control inflammation. Our case studies also suggest CYC is an effective therapy for severe cases of RP refractory to CS alone. Disclosure: M. Solaiman:None. O. Ogunbambi: None. Rheumatology, Northampton General Hospital, Northampton, UNITED KINGDOM Introduction: Retroperitoneal fibrosis is a rare condition characterised by the presence of inflammatory and fibrous retroperitoneal tissue that often encases the ureters or abdominal organs. It is a systemic autoimmune disease that may arise as a primary aortitis that elicits a periaortic fibroinflammatory response. It may be idiopathic (immune-mediated) or secondary to other causes such as drugs (ergot-derivatives, methysergide, bromocriptine, beta blockers, methyldopa), biological agents (etanercept, TNF-alpha blocker, infliximab), infections (TB, histoplasmosis, actinomycosis), malignancy, radiation therapy and surgery. Idiopathic forms account for over 70% of cases and are either IgG4 or non IgG4 related. Case description: A 58 year old lady with chronic back pain secondary to a prolapsed intervertebral disc, migraine and depression, presented to A&E with a one-week history of worsening stabbing epigastric, left flank and groin pain, radiating to the back, associated with urinary retention, hesitancy and incomplete emptying of her bowels. She also complained of oral and genital ulcers as well as night sweats, nausea, fatigue, weight and appetite loss. She reported early morning stiffness affecting her shoulders, hands, pelvis and hips bilaterally. She has had a previous hysterectomy due to uterine cancer and a family history of lung and CNS malignancy was noted. She denied any recent travel history, contact with TB patients, and any exposure to asbestos. She was not sexually active and was not on any ergot derivatives for migraine. Examination findings were unremarkable apart from a tender epigastrium, oral and genital ulcerations. She has recently been investigated by gastroenterology and vascular team for longstanding back and abdominal symptoms that were experienced for the last 2-3 years. She was found to have an infra-renal abdominal aortic aneurysm measuring 3.8 cm with severe retroperitoneal fibrosis but no ureteric obstruction according to the CT abdomen and pelvis (2017). Subsequently, multiple investigations including autoimmune screen, infection screen and tumour markers were carried out to exclude secondary causes of retroperitoneal fibrosis. Both gastroscopy and colonoscopy including biopsy were not suggestive of cancer. CT angiogram aorta was performed following the recent admission, which showed a 3.8 cm abdominal aortic aneurysm, peri aortitis, moderate size hydro-nephrosis and right upper hydro-ureter. She was then started on prednisolone 1mg/ kg with gastric and bone protection as well as acyclovirprophylaxis. Discussion: Although the diagnosis is often made by imaging studies, including CT scan or MRI, a definitive diagnosis may require a biopsy. However, many clinicians do not perform a biopsy in patients with imaging studies demonstrating findings typical of retroperitoneal fibrosis unless the patient is having surgery. The role of glucocorticoids is of paramount importance in treating retroperitoneal fibrosis and the extent of the diseasecanbemonitoredwitharoutine PETscan.Notably,urgentclinical advice should be sought from the renal team for ureteric stent insertion if hydronephrosis is complicated byobstructiveuropathy.
IDIOPATHIC RETROPERITONEAL FIBROSIS (POSSIBLY IG
Key Learning Points: Firstly, the initial clinical features of idiopathic or secondary retroperitoneal fibrosis are nonspecific, and the diagnosis is often not considered until there is significant organ (most commonly kidney) involvement. Most patients have ureteral obstruction and renal impairment by the time they come to medical attention. In addition, many patients have anaemia, possibly related to renal insufficiency or chronic inflammation. Furthermore, among patients with presumed idiopathic retroperitoneal fibrosis, ANA, IgG4, ASMA, ANCA, TFTs, thyroid microsomal antibody and thyroglobulin are normally checked. ANA has been reported to be positive in up to 50% of cases and antibodies against thyroid microsome and thyroglobulin are positive in approximately 25% of cases. Introduction: MAGIC syndrome (mouth and genital ulcers with inflamed cartilage syndrome) is a systemic condition consisting of an overlap of Behc¸et's disease (BD) and relapsing polychondritis (RP). We present the case of a 40 year old woman with MAGIC syndrome who developed a saccular aneurysm of the aortic arch as well as right femoral and popliteal aneurysms, ultimately resulting in emergency above knee amputation. We also discuss the development of these complications despite the patient being on systemic immunosuppressive therapies (azathioprine, thalidomide, infliximab, cyclophosphamide and tocilizumab). Case description: A 34 year old female was referred to City Hospital Birmingham's Behc¸et's Syndrome Centre of Excellence in September 2012. This was following an 18 year history of BD and a six year history of RP. The clinical features of these two conditions led to the diagnosis of MAGIC syndrome. She was referred to City Hospital as her symptoms were not controlled despite attempts with multiple different immunosuppressive therapies (azathioprine, thalidomide, ciclosporine, and prednisolone). Examination at that time revealed evidence of active synovitis in the left hand metacarpophalangeal joints, both wrists and both midtarsal joints. Ophthalmology assessment revealed bilateral scleral thinning with evidence of partially suppressed scleritis. A decision was made to start infliximab, at a dose of 5mg/kg, at intervals of 0, 2 and six weeks and eight-weekly thereafter. Bloods showed: CRP 98mg/L; ESR 99mm/ hr; normal immunoglobulins apart from slightly reduced IgG at 4.9 g/L; Hb 13.1g/L with raised MCV 101fL. Other bloods were unremarkable including liver function tests, rheumatoid factor, complements, anti-nuclear antibody, anti-neutrophil cytoplasmic antibodies, and protein strip. In October 2012, before receiving her 2nd dose of infliximab, the patient reported shortness of breath. This was associated with a reduced exercise tolerance and production of green sputum. Chest x-ray showed extensive air space shadowing bilaterally, and a large area of consolidation in the right mid zone. Given the immunosuppressive medications the patient had previously received, opportunistic infections were considered. High resolution CT showed bilateral patchy ground glass changes through all lung zones. Bronchoscopy was normal and viral polymerase chain reaction (PCR) and mycoplasma were negative. A diagnosis of pneumocystis jirovecii(PJP) (HIV negative) was made by PCR. Azathioprine and ciclosporine were stopped and treatment of PJP with septrin was commenced. Following the completion of her treatment for PJP, our patient continued her infliximab regime and was restarted on azathioprine. She remained on septrin prophylaxis and acyclovir was also commenced prophylactically following an episode of herpes zoster infection. She tolerated these treatments well with no further complications from the infliximab. In May 2013, the patient presented acutely with right leg pain. CT angiogram showed an extremely large fusiform aneurysm of the proximal right popliteal artery which measured 9cm in craniocaudal diameter anda number of scattered patchy areas of bone sclerosis in the right femur and tibia which were in keeping with bone infarcts. A right sided endovascular popliteal sheath graft was subsequently inserted and the patient was commenced on dual antiplatelet therapy. During admission, the patient was commenced on her first dose of intravenous (IV) cyclophosphamide (15mg/kg) and given two doses of IV methylprednisolone. The patient subsequently developed a right below knee deep vein thrombosis (DVT). A decision was made not to anticoagulate the patient. Throughout 2013, she continued to receive IV cyclophosphamide on a three-weekly basis. The intervals were shortened to two-weekly during episodes of poor disease control.In August 2013, she was found to have ischaemia of the right 1st and 2nd toes. Following further investigation with Doppler ultrasound she was found to have a femoral DVT. The patient's dual antiplatelet regime was stopped and she was subsequently commenced on enoxaparin. In September 2013, the patient developed a rupture of a right common femoral artery aneurysm requiring emergency repair with a Dacron graft in Guy's and St Thomas' Foundation Trust. Histopathology showed vasculitis within the arterial wall. Our patient continued to experience problems with distal wound necrosis in the groin. In February 2014, a repeat CT angiogram showed stenotic lesions in both the right groin graft and popliteal stent. Following discussion in the multidisciplinary team meeting, it was decided that angioplasty was needed for both lesions. This was carried out with good results. In June 2014, the patient, now 36 years old, again developed shortness of breath. As part of her investigations a CT thorax was performed. The CT scan showed a large saccular aneurysm of the brachiocephalic artery, which appeared to extendto the level of the bifurcation of the right subclavian and common carotid arteries. There was also a 4.4cm saccular aneurysm arising from the inferior surface of the arch at the level of the left subclavian artery. She underwent replacement of the aortic arch with a branched graft and frozen elephant trunk procedure with the branches of the arch graft going to the left common, right carotid, and the right subclavian arteries. An important and unexpected finding at the time of surgery was a large 3-3.5cm right coronary artery (RCA) aneurysm. This was considered high risk for rupture and required immediate treatment. The aneurysm was ligated proximally and distally and a saphenous vein graft was constructed to the posterior descending RCA. The patient subsequently developed right ventricular failure and required extra-corporeal membrane oxygenation (ECMO) for cardiovascular support. This resulted in a prolonged ICU stay. At her post-operative appointment in October 2014, the patient was mobilising with crutches and was able to stand and walk short distances independently. However, in December 2014, shepresentedwith acutelimb ischaemia and required an emergency right sided above knee amputation. In March 2015, it was decided that the patient would start on tocilizumab. By 2016, the patient's disease was clinically in remission. However, towards the end of 2016, the patient experienced a left-sided upper lobe collapse with lesions at the left lung hilum. Bronchoscopy showed RP causing local bronchial stenosis.A repeat CT scan two weeks later, following acourse of steroids, showed a resolution of the lobar collapse and lung lesions. As of 2018, the patient remains on tocilizumab. Her patient index score for BD is 1 and her transformed index score is 3, which indicates low disease activity. She reports to be happy with regard to her disease activity. Clinically our patient's disease is stable currently, however, it remains precarious as she is at high risk of developing complications from her conditions and as aresult of immunosuppressive therapy. Discussion: The number of reported cases of MAGIC syndrome are far and few between. Even at City Hospital Birmingham's Behc¸et's Syndrome Centre, the number of cases of MAGIC syndrome is low. Therefore, further research and patient observation is needed for us to fully establish our understanding of MAGIC syndrome. Key Learning Points: MAGIC syndrome is a complex syndrome that requires consideration and a high index of suspicion in patients with BD who present with nasal, tracheal, or auricular symptoms, which may indicate RP. Patients with MAGIC syndrome can develop complications of BD and RP despite systemic immunosuppression. The balance between continual increases of immunosuppression for clinical benefit versus the risk of side effects can be extremely challenging. Therefore, a high degree of suspicion mustbe employed whenreviewing patients with MAGIC syndrome to ensure that new symptoms from the patient's disease or from the side effects of immunosuppression are not missed. Complex rheumatological conditions such as MAGIC syndrome present clinicians with challenges when developing management strategies. A personalised and patient-tailored approach is required before and during treatment, with an ability to adapt to what can be a constantly evolving clinical picture. Educating patients about their disease and how to manage day-todayaspects of their condition is afundamental partof managementwhich develops their role as an active informed participant in their care. This is one of the major aspects of the multidisciplinary approach at the Behc¸et's Syndrome Centres of Excellence. This holistic approach helps patients understand their conditionand access timely and appropriate care. Disclosure: J. Caplan: None. J. Lee Siew Hua: None. P. Chandratre: None.
ATYPICAL PRESENTATION OF ANTI-SIGNAL RECOGNITION PARTICLE ANTIBODY POSITIVE MYOSITIS WITH PROFOUND EXTRA-MUSCULAR FEATURES
Abeer Ghuman 1 and Richard Stratton 1 1 Rheumatology, Royal Free Hospital, London, UNITED KINGDOM Introduction: Autoantibodies against signal recognition particle (SRP) were first reported in the serum of a patient with polymyositis. Anti-SRP antibodies are a rare cause of myopathy; they are found in roughly 5% of all inflammatorymyopathies.Based onclinical observations,it isreported that anti-SRP antibodies are associated with the severe and rapidly progressive muscle weakness, marked elevation of creatine kinase (CK) and a necrotising myopathy on histology. Extramuscular manifestations are commonly low in incidence. Patients with anti-SRP positive myositis tend toshowagood initial responsetohigh dose steroid therapy butthe myositis then tends to relapse leading to the requirement of high cumulative doses of steroid. As well as steroid therapy these patients do commonly require additional immunotherapy. No particular immunosuppressive agent or treatment regime has been found to be consistently effective or superiorinthese patients. Wedescribeacase of anti-SRPpositivemyositis presenting with profound extramuscular features including lung and cardiac involvement in the absence of limb, trunk or bulbar weakness. This patient showed a marked clinical response to high dose steroids and early B cell depletionwithrituximab. Case description: A 63 year old Malaysian gentleman developed an acute onset of a pruritic rash over his back. The rash was erythematous, flat and confluent and spread at sites where he scratched. The rash continued to progress despite topical corticosteroids. He was given a seven day course of prednisolone from his general practitioner (GP) which settled the rash. As the rash subsided he developed acute onset of Raynauds symptoms. He then developed rapidly progressive shortness of breath over the course of three months. His exercise tolerance became limited to a few hundred yards. There was no associated cough or chest pain. Associated with this shortness of breath was severe fatigue. He developed sweats and fevers at night. There was no history of limb weakness or dysphagia. He has no significant past medical history and was on no regular medications. He is a lifelong non-smoker. He reattended his GP surgery who suspected an autoimmune aetiology for his symptoms and sent an autoimmune screen. The anti-nuclear antibody (ANA) returned strongly positive and he was referred on to rheumatology clinic. On arrival in rheumatology clinic three months after onset of respiratory symptoms he was markedly hypoxic with saturations of 90% on air and he was tachypnoeic with a respiratory rate of 30. He was tachycardic at 100 beats per minute. He spiked fevers of over 39 degrees celsius typically at night during his inpatient stay. He had a mild synovitis affecting his metacarpophalangeal and proximal interphalangeal joints bilaterally. There was no visible rash. Chest examination revealed bibasal fine inspiratory crackles. There was nofocal neurology and he had anormal medical research council (MRC) muscle score at presentation. Bloods showed raised inflammatory markers with an erythrocyte sedimentation rate (ESR) 103mm/hr and C-reactive protein 36mg/ml. CK was high at 1083unit/L and troponin T 368ng/L. Renal function was normal and urine dip was negative for blood and protein. Autoimmune screen revealed positive ANA 1:5120 nucleolar, negative extranuclear antigen (ENA), normal complement and normal double stranded DNA. The myositis panel came back as positive for anti-SRP antibodies He had a chest x-ray which showed bilateral pulmonary infiltrates. High resolution computed tomography (CT) chest showed areas of interstitial thickening and atelectasis within the middle lobe, lingula and the lower lobes bilaterally with scattered areasinthe apices.Therewastraction dilatation ofthedistalairways involving both lower lobes and shallow bilateral effusions. There was no lymphadenopathy. The imaging was discussed at a respiratory multidisciplinary meeting, the findings suggested a fibrotic process which were not entirely typical of either non specific interstitial pneumonia (NSIP) or usual interstitial pneumonia (UIP). Lung function showed preserved forced expiratory volume (FEV1) and forced vital capacity (FVC) but a low transfer factor(DLCO).Electrocardiogram(ECG)showed sinustachycardia. Due to the raised troponin he went on to have a cardiac magnetic resonance imaging (MRI) which showed late gadolinium enhancement at the level of the superior left ventricle/right ventricle insertion point which minimally extend into the septum (non ischaemic distribution). The finding on T1 and T2 suggested an early stage of cardiac involvement of connective tissue disorder. An electromyogram (EMG) showed focal myopathic features only in the right iliapsoas muscle with evidence of some muscle membraneinstability.Therewasnoassociatedclinicalevidenceofweakness in this muscle distribution. Nail fold capillaroscopy demonstrated abnormal capillaries with dropout from the rows. The diagnosis of myositis with lung, cardiac and joint involvement was made. He was treated with three days of intravenous (IV) methylprednisolone and then 40mg oral prednisolone once daily. He then had Rituximab infusion at a dose of 1g two weeks apart. He was then started on mycophenalate mofetil at 500mg BD as maintenance therapy. He showed a dramatic improvement with treatment -he was no longer oxygen dependent after three days of intravenous steroid and was saturating at 98% on air. His synovitis resolved. His ESR and CRP reduced to normal. His CK level came down to 446unit/L. He is currently being followed up as an outpatient and remains on low dose oral steroid and mycophenalatemofetil. Discussion: Anti-SRP antibodies are typically considered serological markers of severe necrotising myopathy. The largest retrospective case study of one hundred anti-SRP positive patients reported that all the patients presented with weakness and reported low incidence of
